Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 1, 2010, Pages 181-185

  Ozkan, Metin ^a   Akbudak, Ismail Hakki ^a   Deniz, Kemal ^a   Dikilitas, Mustafa ^a   Dogu, Gamze Gokoz ^b   Berk, Veli ^a   Karaca, Halit ^a   Er, Ozlem ^c   Altinbas, Mustafa ^d  

^a ERCIYES UNIVERSITY   (Turkey)

^b Kayseri State Hospital of Research and Education   (Turkey)

^c ACIBADEM HOSPITAL   (Turkey)

^d DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Advanced gastric cancer; Cisplatin based chemotherapy; ERCC1

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77955834779     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hundahl SA, Phillips JL, Menck HR (2000). The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy. Cancer, 88, 921-32.
2. Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8.
3. Catalano V, Labianca R, Beretta GD, et al (2009). Gastric cancer. Crit Reviews Oncol/Hematol,71, 127-64.
4. Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9.
5. Sancar A, Reardon JT (2004). Nucleotide excision repair in E. coli and man. Adv Protein Chem, 69, 43-71.
6. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E (1993). Cisplatin sensitivity/resistans in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis, 23, 3237-40.
7. Metzger R, Leichman CG, Danenberg KD, et al (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol, 16, 309-16.
8. Lord RV, Brabender J, Gandara D, et al (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91.
9. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D (2000). ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer, 89,453-7.
10. Codegoni AM, Broggini M, Pitelli MR, et al (1997). Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol, 65, 130-7.
11. Shirota Y, Stoehlmacher J, Brabender J, et al (2001). ERCC1and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 19, 4298-304.
12. Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91.
13. Waters JS, Norman A, Cunningham D, et al (1999). Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer, 80, 269- 72.
14. Matsubara J, Nishina T, Yamada Y, et al (2008). Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer, 98, 832-9.
15. Altinbas M, Er O, Ozkan M, et al (2005). Irinotecan plus cisplatin combination against metastatic gastric cancer phase II study. Med Oncol, 22, 153-60.
16. Aykan NF, Idelevich E (2008). The role of UFT in advanced gastric cancer. Ann Oncol, 19, 1045-52.
17. Jeen YT, Yoon SY, Shin SW, et al (2001). Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer, 91, 2288-93.
18. Idelevich E, Karminsky N, et al (2007). Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as firstline chemotherapy in metastatic gastric cancer. Acta Oncol, 46, 324-9.
19. Malet-Martino M and Martino R (2002). Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist, 7, 288-323.
20. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A Report of the V325 Study Group. J Clin Oncol, 24, 4991-7.